drugset / Trial / NCT00686621

Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)

NCT00686621

Expanded access Approved for marketing Merck Sharp & Dohme LLC

Summary

The purpose of this study is to provide posaconazole compassionate treatment to patients with invasive fungal infections: 1) which are resistant to standard antifungal therapies; 2) for which there are no effective therapies; 3) with a prior history of serious, severe, or life-threatening toxicities while receiving standard antifungal therapies, or 4) with pre-existing organ dysfunction which precludes the use of standard antifungal therapies.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Posaconazole Small molecule 200 mg Oral
Subject Posaconazole Small molecule 400 mg Oral